FR21C1039I1 - - Google Patents

Info

Publication number: FR21C1039I1
Authority: FR; France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-15

Filing date

2021-09-09

Publication date

2021-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1039(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-09-09 Application filed filed Critical

2021-10-15 Publication of FR21C1039I1 publication Critical patent/FR21C1039I1/fr

2022-09-02 Application granted granted Critical

2022-09-02 Publication of FR21C1039I2 publication Critical patent/FR21C1039I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FR21C1039C 2014-05-15 2021-09-09 COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY Active FR21C1039I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461993839P	2014-05-15	2014-05-15
PCT/EP2015/060343 WO2015173181A1 (en)	2014-05-15	2015-05-11	Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number	Publication Date
FR21C1039I1 true FR21C1039I1 (en)	2021-10-15
FR21C1039I2 FR21C1039I2 (en)	2022-09-02

Family

ID=53175048

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1039C Active FR21C1039I2 (en)	2014-05-15	2021-09-09	COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY

Country Status (36)

Country	Link
US (1)	US9969754B2 (en)
EP (3)	EP3663296B1 (en)
JP (1)	JP6236173B2 (en)
KR (2)	KR102256013B1 (en)
CN (1)	CN106459092B (en)
AR (2)	AR100442A1 (en)
AU (1)	AU2015261046C1 (en)
BR (1)	BR112016026205B1 (en)
CA (1)	CA2948561C (en)
CL (1)	CL2016002836A1 (en)
CR (1)	CR20160518A (en)
DK (1)	DK3143025T3 (en)
EA (2)	EA035068B1 (en)
ES (2)	ES2761423T3 (en)
FR (1)	FR21C1039I2 (en)
HR (2)	HRP20230637T1 (en)
HU (2)	HUE046491T2 (en)
IL (2)	IL248653B (en)
LT (1)	LTC3143025I2 (en)
MA (2)	MA51988A (en)
MX (1)	MX371050B (en)
MY (1)	MY174284A (en)
NL (1)	NL301128I2 (en)
NO (2)	NO2021035I1 (en)
NZ (1)	NZ725008A (en)
PE (1)	PE20170128A1 (en)
PH (1)	PH12016502081B1 (en)
PL (2)	PL3143025T3 (en)
PT (1)	PT3143025T (en)
RS (1)	RS59718B1 (en)
SG (1)	SG11201609497TA (en)
SI (2)	SI3143025T1 (en)
TW (1)	TWI667239B (en)
UA (1)	UA119670C2 (en)
WO (1)	WO2015173181A1 (en)
ZA (1)	ZA201607026B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA037123B1 (en)	2012-02-10	2021-02-09	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Compounds for treating spinal muscular atrophy
JP6689197B2 (en)	2013-08-19	2020-04-28	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Screening method
US10882868B2 (en) *	2014-05-15	2021-01-05	Hoffmann-La Roche Inc.	Compounds for treating spinal muscular atrophy
EP3298017B1 (en)	2015-05-20	2019-08-14	H. Hoffnabb-La Roche Ag	Compounds for treating spinal muscular atrophy
EP3310169B1 (en)	2015-05-30	2023-05-17	PTC Therapeutics, Inc.	Methods for modulating rna splicing
BR112018009281B1 (en)	2015-11-12	2023-10-31	F. Hoffmann-La Roche Ag	COMPOSITIONS TO TREAT SPINAL MUSCULAR ATROPHY AND THEIR USE
AR106652A1 (en) *	2015-11-12	2018-02-07	Hoffmann La Roche	COMPOUNDS TO TREAT AMIOTROPHIC LATERAL SCLEROSIS
JP6872550B2 (en)	2015-12-10	2021-05-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Crosslinked piperidine derivative
MX382671B (en)	2015-12-10	2025-03-13	Ptc Therapeutics Inc	COMPOUNDS FOR USE IN THE TREATMENT OR AMENDING OF HUNTINGTON'S DISEASE
JP2019535789A (en) *	2016-11-28	2019-12-12	ピーティーシーセラピューティクス，インコーポレーテッド	Methods for modulating RNA splicing
JP7376471B2 (en)	2017-06-05	2023-11-08	ピーティーシーセラピューティクス，インコーポレイテッド	Compounds to treat Huntington's disease
CN111372611A (en)	2017-06-14	2020-07-03	Ptc医疗公司	Methods of modifying RNA splicing
MX2019015580A (en)	2017-06-28	2020-07-28	Ptc Therapeutics Inc	Methods for treating huntington's disease.
MX2019015578A (en)	2017-06-28	2020-07-28	Ptc Therapeutics Inc	Methods for treating huntington's disease.
MX2020002711A (en) *	2017-09-22	2020-07-20	Hoffmann La Roche	PROCESS FOR THE PREPARATION OF 7-(4,7-DIAZAESPIRE[2.5]OCTAN-7-IL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-IL)PYRIDO[1,2-A ]PYRIMIDIN-4- ONE.
AU2018344402B2 (en) *	2017-10-03	2024-08-29	F. Hoffmann-La Roche Ag	New treatment of SMA
JP7399870B2 (en)	2018-03-27	2023-12-18	ピーティーシーセラピューティクス，インコーポレイテッド	Compounds to treat Huntington's disease
EA202092899A1 (en)	2018-06-27	2021-05-14	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE
WO2020004594A1 (en)	2018-06-27	2020-01-02	株式会社リボルナバイオサイエンス	Prophylactic or therapeutic agent for spinal muscular atrophy
LT3814357T (en)	2018-06-27	2024-06-25	Ptc Therapeutics, Inc.	Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en)	2018-06-27	2023-06-27	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating Huntington's disease
TWI861018B (en)	2018-10-19	2024-11-11	瑞士商赫孚孟拉羅股份公司	New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
EP3982970A1 (en)	2019-06-12	2022-04-20	F. Hoffmann-La Roche AG	New treatment of sma
EP4004003A1 (en)	2019-07-31	2022-06-01	Teva Pharmaceuticals International GmbH	Solid state forms of risdiplam and process for preparation thereof
WO2021207550A1 (en) *	2020-04-08	2021-10-14	Remix Therapeutics Inc.	Compounds and methods for modulating splicing
WO2022048675A1 (en) *	2020-09-07	2022-03-10	苏州科睿思制药有限公司	Crystal form of risdiplam, preparation method therefor, and use thereof
WO2022162107A1 (en)	2021-02-01	2022-08-04	Sandoz Ag	Crystalline form of risdiplam
JP2024510487A (en) *	2021-03-17	2024-03-07	エフ．ホフマン－ラロシュアーゲー	Novel thiadiazolopyrimidone derivatives
CA3212341A1 (en)	2021-03-17	2022-09-22	F. Hoffmann-La Roche Ag	New thiazolopyrimidinone derivatives
AU2022237836B2 (en) *	2021-03-18	2024-07-04	F. Hoffmann-La Roche Ag	Process for preparing risdiplam
WO2023057404A1 (en)	2021-10-06	2023-04-13	F. Hoffmann-La Roche Ag	Novel combined administration
CN118005654A (en) *	2022-04-18	2024-05-10	深圳市塔吉瑞生物医药有限公司	Substituted pyridopyrimidinone compounds, compositions containing the same and uses thereof
WO2023240236A1 (en)	2022-06-10	2023-12-14	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) *	2022-09-26	2024-04-04	Natco Pharma Limited	Improved process for the preparation of risdiplam and its intermediates
US20240173325A1 (en)	2022-10-14	2024-05-30	Genentech, Inc.	Methods for treating spinal muscular atrophy
CN120530115A (en) *	2023-01-21	2025-08-22	哈曼菲诺化学有限公司	Preparation method of lisapram, novel intermediate and preparation method thereof
WO2024218207A1 (en)	2023-04-20	2024-10-24	F. Hoffmann-La Roche Ag	Thieno[3,2-b]pyridine derivatives
WO2024251925A1 (en)	2023-06-09	2024-12-12	F. Hoffmann-La Roche Ag	Inducible gene expression system
CN117050096A (en) *	2023-07-17	2023-11-14	杭州诺澳生物医药科技有限公司	Preparation method of risperidone
US20250144031A1 (en)	2023-10-27	2025-05-08	Hoffmann-La Roche Inc.	Composition for treating spinal muscular atrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE232863T1 (en) *	1996-08-06	2003-03-15	Pfizer	6,6- OR 6,7-BICYCLIC DERIVATIVES CONTAINING SUBSTITUTED PYRIDO OR PYRIMIDO GROUPS
US20100267712A1 (en)	2007-09-27	2010-10-21	The United States of America, as represented by the Secretary, Department of Health and	Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) *	2008-05-27	2009-12-17	Ptc Therapeutics, Inc.	Methods for treating spinal muscular atrophy
KR20100012134A (en) *	2008-07-28	2010-02-08	신호열	A mouse for notebook-pc
US8932818B2 (en)	2008-08-13	2015-01-13	Ptc Therapeutics, Inc.	Screening assays for compounds that modulate programmed ribosomal frameshifting
WO2010019326A1 (en) *	2008-08-14	2010-02-18	Cardiac Pacemakers, Inc.	Performance assessment and adaptation of an acoustic communication link
USRE47689E1 (en) *	2011-12-30	2019-11-05	Ptc Therapeutics, Inc.	Compounds for treating spinal muscular atrophy
CA2862084C (en) *	2012-01-26	2021-05-11	Ptc Therapeutics, Inc.	1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy
EA037123B1 (en) *	2012-02-10	2021-02-09	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Compounds for treating spinal muscular atrophy
US9212209B2 (en)	2012-07-13	2015-12-15	Indiana University Research And Technology Corporation	Screening methods for spinal muscular atrophy
BR112018009281B1 (en)	2015-11-12	2023-10-31	F. Hoffmann-La Roche Ag	COMPOSITIONS TO TREAT SPINAL MUSCULAR ATROPHY AND THEIR USE

2015
- 2015-05-11 RS RS20191541A patent/RS59718B1/en unknown
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/en active Active
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/en unknown
- 2015-05-11 PL PL15721701T patent/PL3143025T3/en unknown
- 2015-05-11 ES ES15721701T patent/ES2761423T3/en active Active
- 2015-05-11 UA UAA201612716A patent/UA119670C2/en unknown
- 2015-05-11 CA CA2948561A patent/CA2948561C/en active Active
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/en unknown
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/en active Active
- 2015-05-11 SI SI201531021T patent/SI3143025T1/en unknown
- 2015-05-11 ES ES19200058T patent/ES2949660T3/en active Active
- 2015-05-11 EA EA201692280A patent/EA035068B1/en active Protection Beyond IP Right Term
- 2015-05-11 BR BR112016026205-0A patent/BR112016026205B1/en active IP Right Grant
- 2015-05-11 PT PT157217019T patent/PT3143025T/en unknown
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/en unknown
- 2015-05-11 EA EA202090486A patent/EA202090486A3/en unknown
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 SI SI201531952T patent/SI3663296T1/en unknown
- 2015-05-11 DK DK15721701T patent/DK3143025T3/en active
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/en active Active
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/en active Active
- 2015-05-11 MA MA051988A patent/MA51988A/en unknown
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/en active Active
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/en unknown
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/en not_active Withdrawn
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/en not_active Ceased
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-11 MA MA39995A patent/MA39995B1/en unknown
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/en active Active
- 2015-05-11 PH PH1/2016/502081A patent/PH12016502081B1/en unknown
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 MX MX2016014547A patent/MX371050B/en active IP Right Grant
- 2015-05-11 CR CR20160518A patent/CR20160518A/en unknown
- 2015-05-11 HR HRP20192159TT patent/HRP20192159T1/en unknown
- 2015-05-14 TW TW104115433A patent/TWI667239B/en active
- 2015-05-14 AR ARP150101500A patent/AR100442A1/en not_active Application Discontinuation
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/en unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/en active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/en unknown
- 2021-09-14 LT LTPA2021010C patent/LTC3143025I2/lt unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/en unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/en unknown
2023
- 2023-12-01 AR ARP230103289A patent/AR131260A2/en unknown
2025
- 2025-08-14 NO NO2025038C patent/NO2025038I1/en unknown

Also Published As

Publication number	Publication date
KR102213740B1 (en)	2021-02-09
KR20170003687A (en)	2017-01-09
UA119670C2 (en)	2019-07-25
JP6236173B2 (en)	2017-11-22
PE20170128A1 (en)	2017-03-16
IL248653B (en)	2019-11-28
HRP20230637T1 (en)	2023-09-29
SI3143025T1 (en)	2020-01-31
CN106459092A (en)	2017-02-22
LTC3143025I2 (en)	2023-11-10
MA51988A (en)	2021-01-20
HUS2100037I1 (en)	2021-10-28
DK3143025T3 (en)	2019-12-09
EP3663296B1 (en)	2023-05-17
JP2017515863A (en)	2017-06-15
EP3143025B1 (en)	2019-10-09
CA2948561C (en)	2019-10-22
EA202090486A2 (en)	2020-06-30
HRP20192159T1 (en)	2020-02-21
IL270027B (en)	2020-08-31
SI3663296T1 (en)	2023-08-31
HUE046491T2 (en)	2020-03-30
EP3663296A1 (en)	2020-06-10
AU2015261046A1 (en)	2016-10-27
MA39995B1 (en)	2019-11-29
TW201609738A (en)	2016-03-16
ZA201607026B (en)	2022-05-25
US20170197990A1 (en)	2017-07-13
PH12016502081A1 (en)	2017-01-09
KR20210014219A (en)	2021-02-08
EP4241772A3 (en)	2023-11-15
EA201692280A1 (en)	2018-07-31
PH12016502081B1 (en)	2022-11-23
EP4241772A2 (en)	2023-09-13
CA2948561A1 (en)	2015-11-19
CL2016002836A1 (en)	2017-04-21
RS59718B1 (en)	2020-01-31
AR100442A1 (en)	2016-10-05
EA035068B1 (en)	2020-04-23
PL3663296T3 (en)	2023-08-07
NL301128I2 (en)	2021-10-25
IL248653A0 (en)	2017-01-31
LTPA2021010I1 (en)	2021-10-11
BR112016026205A2 (en)	2017-08-15
BR112016026205A8 (en)	2021-07-20
CR20160518A (en)	2017-02-21
PT3143025T (en)	2019-12-03
FR21C1039I2 (en)	2022-09-02
WO2015173181A1 (en)	2015-11-19
SG11201609497TA (en)	2016-12-29
US9969754B2 (en)	2018-05-15
CN106459092B (en)	2019-10-15
NO2021035I1 (en)	2021-09-10
TWI667239B (en)	2019-08-01
AU2015261046C1 (en)	2019-07-25
AU2015261046B2 (en)	2019-04-18
EA202090486A3 (en)	2020-08-31
PL3143025T3 (en)	2020-03-31
AR131260A2 (en)	2025-03-05
NL301128I1 (en)	2021-09-22
KR102256013B1 (en)	2021-05-26
BR112016026205B1 (en)	2021-12-07
ES2949660T3 (en)	2023-10-02
MX2016014547A (en)	2017-02-23
NZ725008A (en)	2019-11-29
NO2025038I1 (en)	2025-08-14
EP3143025A1 (en)	2017-03-22
MY174284A (en)	2020-04-01
MX371050B (en)	2020-01-14
ES2761423T3 (en)	2020-05-19

Publication	Publication Date	Title
NL301128I1 (en)	2021-09-22
BR112016016552A2 (en)	2017-08-08
BR112016016225A2 (en)	2017-08-08
BR112016016602A2 (en)	2017-08-08
BR112016016245A2 (en)	2017-10-03
BR112016018948A2 (en)	2017-08-15
BR112016013761A2 (en)	2017-08-08
BR112016018580A2 (en)	2017-08-08
BR112016018468A2 (en)	2017-08-08
BR112016016451A2 (en)	2017-08-08
BR112016011585A2 (en)	2017-08-08
BR112016019248A2 (en)	2017-08-15
BR112016018564A2 (en)	2017-08-08
BR112016015666A2 (en)	2017-08-08
BR112016016268A2 (en)	2017-08-08
BR112016015915A2 (en)	2017-08-08
BR112016015911A2 (en)	2017-08-08
BR112016019471A2 (en)	2017-08-15
BR112016018896A2 (en)	2017-08-15
BR112016017717A2 (en)	2017-08-08
BR112016015071A2 (en)	2017-08-08
BR112016018749A2 (en)	2017-08-08
BR112016015965A2 (en)	2017-08-08
BR112016015751A2 (en)	2017-08-08
BR112016015651A2 (en)	2017-08-08